Royalty Pharma PLC $RPRX Shares Acquired by Signaturefd LLC

Signaturefd LLC increased its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 17.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,158 shares of the biopharmaceutical company’s stock after buying an additional 464 shares during the period. Signaturefd LLC’s holdings in Royalty Pharma were worth $114,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Royalty Pharma during the 4th quarter worth approximately $246,000. Wellington Management Group LLP grew its holdings in Royalty Pharma by 4.1% during the 4th quarter. Wellington Management Group LLP now owns 18,539 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 733 shares during the last quarter. GAMMA Investing LLC increased its position in Royalty Pharma by 3,146.5% during the first quarter. GAMMA Investing LLC now owns 80,222 shares of the biopharmaceutical company’s stock worth $2,577,000 after buying an additional 77,751 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Royalty Pharma by 22.0% in the first quarter. Parallel Advisors LLC now owns 4,423 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 798 shares during the last quarter. Finally, Merit Financial Group LLC acquired a new stake in shares of Royalty Pharma during the first quarter valued at $252,000. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $36.07 on Friday. The stock has a market capitalization of $21.03 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 2.25 and a beta of 0.60. Royalty Pharma PLC has a one year low of $24.05 and a one year high of $38.00. The company’s 50-day simple moving average is $36.28 and its 200-day simple moving average is $34.55. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%.The firm had revenue of $578.67 million during the quarter, compared to analyst estimates of $750.06 million. Equities analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a dividend of $0.22 per share. The ex-dividend date was Friday, August 15th. This represents a $0.88 annualized dividend and a yield of 2.4%. Royalty Pharma’s dividend payout ratio (DPR) is 50.87%.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of recent research reports. Weiss Ratings restated a “hold (c+)” rating on shares of Royalty Pharma in a report on Saturday, September 27th. Wall Street Zen lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, September 13th. The Goldman Sachs Group began coverage on shares of Royalty Pharma in a research report on Tuesday. They set a “buy” rating and a $42.00 target price on the stock. Citigroup lifted their target price on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 22nd. Finally, Morgan Stanley increased their price target on Royalty Pharma from $51.00 to $54.00 and gave the stock an “overweight” rating in a research note on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $46.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.